Nolomirole

Nolomirole (CHF 1035) is an orally active and selective DA2 dopaminergic receptor/α2-adrenoceptor agonist. Nolomirole attenuates the heart failure signs in the Monocrotaline (HY-N0750) -induced congestive heart failure model. Nolomirole increases cardiac output[1][2][3][4].

Product Specifications

CAS Number

[90060-42-7]

Product Name Alternative

CHF 1035 (free base)

UNSPSC

12352005

Target

Adrenergic Receptor; Dopamine Receptor

Related Pathways

GPCR/G Protein; Neuronal Signaling

Field of Research

Cardiovascular Disease

Smiles

CC(C)C(OC1=C2C(CC(NC)CC2)=CC=C1OC(C(C)C)=O)=O

Molecular Formula

C19H27NO4

Molecular Weight

333.42

References & Citations

[1]1. Afzal M. Recent updates on novel therapeutic targets of cardiovascular diseases. Mol Cell Biochem. 2021 Jan; 476 (1) :145-155. |[2]2. Torp-Pedersen C, et al. A randomised trial of a pre-synaptic stimulator of DA2-dopaminergic and alpha2-adrenergic receptors on morbidity and mortality in patients with heart failure. Eur J Heart Fail. 2008 Jan; 10 (1) :89-95. |[3]3. Tjeerdsma G, et al. Autonomic and hemodynamic effects of a new selective dopamine agonist, CHF1035, in patients with chronic heart failure. Cardiovasc Drugs Ther. 2001 Mar; 15 (2) :139-45. |[4]4. Pasini E, et al. Effect of nolomirole on monocrotaline-induced heart failure. Pharmacol Res. 2004 Jan; 49 (1) :1-5.

Shipping Conditions

Room temperature

Scientific Category

Reference compound1

Clinical Information

No Development Reported